How this company measures up on the fundamentals that matter
West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging products. This segment also provides drug containment solutions in the form of vials, syringes, and cartridges; and self-injection devices; and a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. This segment primarily serves pharmaceutical, diagnostic, and medical device companies. It sells and distributes its products through its sales force and distribution network, contract sales agents, and regional distributors. West Pharmaceutical Services, Inc. was founded in 1923 and is headquartered in Exton, Pennsylvania.
Five compliance checks based on AAOIFI standards — all must pass for ethical clearance
Trading at $304, 51% above fair value of $201. Moderate competitive position. Passes all ethical screens. Ranks better than 62% of screened stocks.
Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data
Trading characteristics and market positioning
Balance sheet strength and cash generation — the foundation of long-term value
SEC Form 4 filings — what company insiders are buying and selling
| Date | Insider | Title | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-05-12 | CAMPBELL SHANE ALDEN | Officer | 769 | — | |
| 2026-05-04 | LOCKHART STEPHEN H | Director | 791 | — | |
| 2026-05-04 | KELLER DEBORAH L | Director | 791 | — | |
| 2026-05-04 | JOSEPH MOLLY E. | Director | 791 | — | |
| 2026-05-04 | FEEHERY WILLIAM F. | Director | 791 | — | |
| 2026-05-04 | MICHELS DOUGLAS A | Director | 791 | — | |
| 2026-05-04 | PUCCI PAOLO | Director | 791 | — | |
| 2026-05-04 | BUTHMAN MARK A | Director | 791 | — | |
| 2026-05-04 | FRIEL ROBERT F | Director | 791 | — | |
| 2026-05-04 | HAUGEN JANET BRUTSCHEA | Director | 791 | — |
Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-15